Faculty Directory
Robert Dreicer headshot
RD

Robert Dreicer

Professor
+1 (434) 924-1775
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Education
Clinical Fellowship, Hem-Onc, University of Wisconsin Medical School
MD, University of Texas Health Sciences Center
Residency, Internal Medicine, Indiana University Medical Center
Biography

Robert Dreicer, MD is deputy director of UVA Cancer Center, serves as the director of solid tumor oncology within the division of hematology/oncology and is a professor of medicine and urology.

Dr. Dreicer received his medical degree from the University of Texas-Houston and a master of science from the University of Texas Graduate School of Biomedical Sciences at Houston. Following his oncology fellowship, Dreicer joined the faculty at University of Iowa, achieving tenure and serving as the associate director of the division of hematology/oncology. He was recruited to Cleveland Clinic, where he served as chair of the department of solid tumor oncology from 2006-2014, before joining UVA Cancer Center in 2015.

Dr. Dreicer’s research interests are in novel therapeutic approaches for urologic cancers including prostate, urothelial and kidney cancers. He is co-chair of the National Cancer Institute’s Genitourinary Oncology Steering Committee and serves as member of the Medical Oncology Test Writing Committee of the American Board of Internal Medicine. He is a member of the Scientific Advisory Board of the Bladder Cancer Advocacy Network.

Dreicer has been named for many years to Top Doctors in America, America’s Best Doctors and America’s Top Doctors for Cancer. He participates regularly in national and international programs devoted to education and research in urologic malignancies.

Recent sponsored awards as provided by ResearchUVA:
MD-CANC ECOG-ACRIN Master
Source: ECOG-ACRIN Cancer Research Group
May 01, 2016 – April 30, 2028
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Source: Exelixis, Inc.
October 22, 2021 – October 21, 2024
MD-INMD-HO - Dreicer - JHU - J1823
Source: Johns Hopkins University, The
September 01, 2018 – December 31, 2023
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Source: ECOG-ACRIN Cancer Research Group
September 01, 2018 – August 31, 2023
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Source: Seattle Genetics, Inc.
July 08, 2020 – July 07, 2023
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Source: Exelixis, Inc.
May 18, 2018 – May 17, 2023
Prostate Cancer Outcomes: An International Registry to ImproveOutcomes in Men with Advanced Prostate Cancer (IRONMAN)
Source: Prostate Cancer Clinical Trials Consortium, LLC
July 24, 2017 – April 24, 2023
MD-INMD-HO Dreicer - Endocyte - VISION
Source: Endocyte, Inc.
December 11, 2018 – December 10, 2022
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Source: Precog, LLC
November 14, 2018 – November 13, 2022
Master Agreement
Source: Coalition Of Cancer Cooperative Groups
August 01, 2000 – July 31, 2022
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
Source: Janssen Research & Development, LLC
July 01, 2019 – June 30, 2022
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Source: ECOG-ACRIN Cancer Research Group
June 25, 2019 – June 24, 2022
MD-CANC-NRG Oncology Dreicer
Source: NRG Oncology Foundation, Inc.
February 09, 2016 – December 31, 2021
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies
Source: Janssen Scientific Affairs, L.L.C.
September 01, 2017 – October 31, 2021
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma ECTCN 9947
Source: Johns Hopkins University, The
December 01, 2016 – February 28, 2021
MD-INMD-HO Dreicer Clovis - ATLAS
Source: Clovis Oncology, Inc.
April 19, 2018 – July 14, 2020
MD-INMD-HO Phase I Study of C6 Ceramide Nanoliposome in Patients with Advanced Solid Tumors
Source: University Of Maryland
September 21, 2016 – November 22, 2019
MD-INMD Frontier Science and Technology Research Foundation Contract #PSAUVAGW00
Source: Frontier Science & Technology Research Foundation,
February 01, 2012 – January 31, 2018
MD-CANC The Johns Hopkins Phase 2 team for the ET-CTN Per Patient
Source: Johns Hopkins University, The
March 21, 2016 – February 28, 2017
MD-CANC The Johns Hopkins Phase 2 team for the ET-CTN Cost Reim. Travel
Source: Johns Hopkins University, The
March 21, 2016 – February 28, 2017
Phase III Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib
Source: Novartis Pharmaceuticals Corporation
August 09, 2010 – December 31, 2015
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)
Source: Medical University of South Carolina The
May 18, 2011 – May 17, 2015
MD-INMD An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
Source: Novartis Pharmaceuticals Corporation
February 09, 2011 – September 10, 2014
  • 2015-2018 Best Doctors in America® List 
  • 2015 One of America's Top Cancer Doctors, Newsweek®